Lunai Bioworks Inc (LNAI) FinancialsLNAILunai Bioworks Inc

Evaluating the bottom line, Lunai Bioworks Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6815.30%, while the net margin is -12278.65%. These profitability ratios, combined with a Return on Equity (ROE) of -325.46%, provide a clear picture of how effectively LNAI converts its operational activities into shareholder value.

In the context of the broader market, LNAI competes directly with industry leaders such as GDTC and MTVA. With a market capitalization of $10.88M, it holds a significant position in the sector. When comparing efficiency, LNAI's gross margin of 100.00% stands against GDTC's 32.69% and MTVA's N/A. Such benchmarking helps identify whether Lunai Bioworks Inc is trading at a premium or discount relative to its financial performance.

Lunai Bioworks has shown a gross margin of 100% in the latest quarter, indicating that it is beginning to generate revenue from its operations, albeit modestly, with total revenue of $20,942. The company has also shown some improvement in net income, with a positive net income of $2,819,021 in Q1 2026, though it reported a net loss of $1,791,404 in Q2 2026.